Forget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THIS

You might have seen that Bitcoin was one of the best performing assets of 2023. It gained 164%. But a crypto millionaire who has been tracking the space for more than a decade has ABANDONED Bitcoin. He found something better.

Click here to find out that this 8,788% cryptocurrency is.

William L. Macias net worth and biography

William Macias Biography and Net Worth

Insider of Immunovant

Presently, William L. Macias is Chief Medical Officer at Immunovant, Inc.

He is also Senior Medical Director at Lilly Research Laboratories.

In his past career he occupied the position of Chief Executive Officer at Focus Biomedical Consulting LLC, Chief Medical Officer of PROMETHERA Biosciences SA and Associate Professor at The Indiana University School of Medicine.

William L. Macias received an undergraduate degree from Marquette University and a doctorate from The Indiana University School of Medicine.

What is William L. Macias' net worth?: The estimated net worth of William L. Macias is at least $9.05 million as of January 18th, 2024. Dr. Macias owns 333,173 shares of Immunovant stock worth more than $9,052,310 as of April 26th. This net worth approximation does not reflect any other assets that Dr. Macias may own. Additionally, Dr. Macias receives a salary of $719,880.00 as Insider at Immunovant. Learn More about William L. Macias' net worth.
How old is William L. Macias?: Dr. Macias is currently 66 years old. There are 6 older executives and no younger executives at Immunovant. Learn More on William L. Macias' age.
What is William L. Macias' salary?: As the Insider of Immunovant, Inc., Dr. Macias earns $719,880.00 per year. There are 2 executives that earn more than Dr. Macias. The highest earning executive at Immunovant is Dr. Peter Salzmann M.B.A., M.D., CEO & Director, who commands a salary of $1,020,000.00 per year. Learn More on William L. Macias' salary.
How do I contact William L. Macias?: The corporate mailing address for Dr. Macias and other Immunovant executives is 320 WEST 37TH STREET, NEW YORK NY, 10018. Immunovant can also be reached via phone at 917-580-3099 and via email at [email protected]. Learn More on William L. Macias' contact information.
Has William L. Macias been buying or selling shares of Immunovant?: William L. Macias has not been actively trading shares of Immunovant during the last ninety days. Most recently, William L. Macias sold 424 shares of the business's stock in a transaction on Thursday, January 18th. The shares were sold at an average price of $41.03, for a transaction totalling $17,396.72. Following the completion of the sale, the insider now directly owns 333,173 shares of the company's stock, valued at $13,670,088.19. Learn More on William L. Macias' trading history.
Who are Immunovant's active insiders?: Immunovant's insider roster includes Peter . (), Eva Barnett (CFO), Julia Butchko (Insider), Douglas Hughes (Director), Mark Levine (Chief Legal Officer and Corporate Secretary), William Macias (Insider), George Migausky (Director), Atul Pande (Director), Peter Salzmann (CEO), and Frank Torti (Director). Learn More on Immunovant's active insiders.
Are insiders buying or selling shares of Immunovant?: During the last twelve months, Immunovant insiders bought shares 1 times. They purchased a total of 1,526,316 shares worth more than $58,000,008.00. During the last twelve months, insiders at the sold shares 33 times. They sold a total of 432,966 shares worth more than $10,713,116.07. The most recent insider tranaction occured on April, 24th when insider Michael Geffner sold 3,261 shares worth more than $94,242.90. Insiders at Immunovant own 4.8% of the company. Learn More about insider trades at Immunovant.
Information on this page was last updated on 4/24/2024.

William L. Macias Insider Trading History at Immunovant

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
1/18/2024	Sell	424	$41.03	$17,396.72	333,173
10/19/2023	Sell	530	$36.80	$19,504.00	336,862
7/19/2023	Sell	426	$24.94	$10,624.44	349,725
4/25/2023	Sell	509	$16.29	$8,291.61	350,151
2/2/2023	Sell	537	$18.24	$9,794.88	262,996
10/21/2022	Sell	341	$9.67	$3,297.47	308,101
7/22/2022	Sell	322	$4.70	$1,513.40	195,626
4/19/2022	Sell	1,392	$4.98	$6,932.16	195,948
1/5/2022	Sell	26,813	$8.28	$222,011.64

William L. Macias Buying and Selling Activity at Immunovant

Immunovant Company Overview

Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that target the neonatal fragment crystallizable receptor for the treatment of myasthenia gravis, thyroid eye disease, chronic inflammatory demyelinating polyneuropathy, and Graves diseases, as well as warm autoimmune hemolytic anemia. The company is headquartered in New York, New York. Immunovant, Inc. operates as a subsidiary of Roivant Sciences Ltd.

Today's Range

Now: $27.17

$26.97

$27.97

50 Day Range

MA: $32.10

$27.17

$38.36

2 Week Range

Now: $27.17

$15.90

$45.58

Volume

1,411,695 shs

Average Volume

1,224,262 shs

Market Capitalization

$3.95 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.65

Forget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THIS

From Paradigm Press | Ad

Click here to find out that this 8,788% cryptocurrency is.

William Macias Biography and Net Worth

What is William L. Macias' net worth?

How old is William L. Macias?

What is William L. Macias' salary?

How do I contact William L. Macias?

Has William L. Macias been buying or selling shares of Immunovant?

Who are Immunovant's active insiders?

Are insiders buying or selling shares of Immunovant?